Your institution may have access to this item. Find your institution then sign in to continue.
Title
Novo Nordisk plans Tianjin insulin.
Abstract
The article reports on the plan of pharmaceutical company Novo Nordisk to build a $400 million insulin production plant in Tianjin, China. The chemical plant will be constructed next to the company's existing Tianjin insulin production base. It will be the company's primary production base for the Asia Pacific region.